Analysis of 572 WHO prequalified pharmaceutical products (2002–2026) highlighting trends across therapeutic areas, applicants, dosage forms, and drug substances. Key patterns show strong dominance of HIV/AIDS, TB, and Malaria, high concentration among leading manufacturers, and clear long-term shifts in global prequalification activity.
View this data story on Datastam